BTG signs Japanese collaboration with Ohara Pharmaceutical

BTG has announced that it has licensed the Japanese rights to glucarpidase to Ohara Pharmaceutical. Under the terms of the licence agreement BTG will also supply glucarpidase to Ohara. Ohara will be responsible for the development programme and registration in Japan. Ohara plans to work in partnership with leading oncologists who will execute clinical trials in a development programme for glucarpidase. An IND application for glucarpidase in Japan was submitted to the Pharmaceuticals and Medical Devices Agency on 5th December. Should glucarpidase be successfully developed and approved, Ohara Pharmaceuticals will have the rights to market and sell glucarpidase in Japan.